Subtypes of Triple-negative Breast Cancer Cell Lines React Differently to Eribulin Mesylate

被引：0

作者：

Braeutigam, Karen ^{[1
]}

Mitzlaff, Katharina ^{[1
]}

Uebel, Lisa ^{[1
]}

Koester, Frank ^{[1
]}

Polack, Stephan ^{[1
]}

Pervan, Mascha ^{[1
]}

Steinert, Gunnar ^{[2
]}

Rody, Achim ^{[1
]}

Liedtke, Cornelia ^{[1
]}

机构：

[1] Univ Med Ctr Schleswig Holstein, Dept Gynecol & Obstet, Campus Lubeck,Ratzeburger Allee 160, D-23538 Lubeck, Germany

[2] Eisai GmbH, Frankfurt, Germany

来源：

ANTICANCER RESEARCH | 2016年 / 36卷 / 06期

关键词：

Triple-negative breast cancer; TNBC; subtypes; eribulin; cell lines; chemosensitivity; proliferation; apoptosis; migration; invasion; gene expression; malignant transformation; PREOPERATIVE CHEMOTHERAPY; MOLECULAR PORTRAITS; HALICHONDRIN-B; IN-VITRO; THERAPY; TUMORS; IDENTIFICATION; SENSITIVITY; PACLITAXEL; TARGET;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: Diagnosis of triple-negative breast cancer (TNBC) is associated with adverse prognosis, particularly in cases of chemotherapy resistance. The goal of this analysis was to compare TNBC vs. non-TNBC cell lines and those of distinct TNBC subtypes with regard to sensitivity to eribulin in vitro. Materials and Methods: Breast cancer cell lines were subjected to cell-viability assays, apoptosis analyses, migration and invasion experiments, and quantitative real-time polymerase chain reaction after exposure to eribulin. Results: Eribulin reduced cell viability in TNBC and nonTNBC cell lines in the sub-nanomolar range. Furthermore, exposure to eribulin induced apoptosis and decreased the rate of migration and invasion. Genes known to induce malignant transformation were differentially expressed after eribulin treatment. Conclusion: Eribulin had a strong antiproliferative effect on breast cancer cell lines, although we did not observe a significant difference between TNBC and non-TNBC cell lines with regard to sensitivity to eribulin.

引用

页码：2759 / 2766

页数：8

共 22 条

[1] Eribulin mesylate exerts specific gene expression changes in pericytes and shortens pericyte-driven capillary network in vitro [J].

Agoulnik, Sergei I. ;

Kawano, Satoshi ;

Taylor, Noel ;

Oestreicher, Judith ;

Matsui, Junji ;

Chow, Jesse ;

Oda, Yoshiya ;

Funahashi, Yasuhiro .

VASCULAR CELL, 2014, 6

[2] Identification of Markers of Taxane Sensitivity Using Proteomic and Genomic Analyses of Breast Tumors from Patients Receiving Neoadjuvant Paclitaxel and Radiation [J].

Bauer, Joshua A. ;

Chakravarthy, A. Bapsi ;

Rosenbluth, Jennifer M. ;

Mi, Deming ;

Seeley, Erin H. ;

Granja-Ingram, Nara De Matos ;

Olivares, Maria G. ;

Kelley, Mark C. ;

Mayer, Ingrid A. ;

Meszoely, Ingrid M. ;

Means-Powell, Julie A. ;

Johnson, Kimberly N. ;

Tsai, Chiaojung Jillian ;

Ayers, Gregory D. ;

Sanders, Melinda E. ;

Schneider, Robert J. ;

Formenti, Silvia C. ;

Caprioli, Richard M. ;

Pietenpol, Jennifer A. .

CLINICAL CANCER RESEARCH, 2010, 16 (02) :681-690

[3] Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study [J].

Cortes, Javier ;

O'Shaughnessy, Joyce ;

Loesch, David ;

Blum, Joanne L. ;

Vahdat, Linda T. ;

Petrakova, Katarina ;

Chollet, Philippe ;

Manikas, Alexey ;

Dieras, Veronique ;

Delozier, Thierry ;

Vladimirov, Vladimir ;

Cardoso, Fatima ;

Koh, Han ;

Bougnoux, Philippe ;

Dutcus, Corina E. ;

Seegobin, Seth ;

Mir, Denis ;

Meneses, Nicole ;

Wanders, Jantien ;

Twelves, Chris .

LANCET, 2011, 377 (9769) :914-923

[4] Triple-negative breast cancer-current status and future directions [J].

Gluz, O. ;

Liedtke, C. ;

Gottschalk, N. ;

Pusztai, L. ;

Nitz, U. ;

Harbeck, N. .

ANNALS OF ONCOLOGY, 2009, 20 (12) :1913-1927

[5] Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer [J].

Hess, Kenneth R. ;

Anderson, Keith ;

Symmans, W. Fraser ;

Valero, Vicente ;

Ibrahim, Nuhad ;

Mejia, Jaime A. ;

Booser, Daniel ;

Theriault, Richard L. ;

Buzdar, Aman U. ;

Dempsey, Peter J. ;

Rouzier, Roman ;

Sneige, Nour ;

Ross, Jeffrey S. ;

Vidaurre, Tatiana ;

Gomez, Henry L. ;

Hortobagyi, Gabriel N. ;

Pusztai, Lajos .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (26) :4236-4244

[6] Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579) [J].

Kaklamani, Virginia G. ;

Jeruss, Jacqueline S. ;

Hughes, Elisha ;

Siziopikou, Kalliopi ;

Timms, Kirsten M. ;

Gutin, Alexander ;

Abkevich, Victor ;

Sangale, Zaina ;

Solimeno, Cara ;

Brown, Krystal L. ;

Jones, Joshua ;

Hartman, Anne-Renee ;

Meservey, Caitlin ;

Jovanovic, Borko ;

Helenowski, Irene ;

Khan, Seema A. ;

Bethke, Kevin ;

Hansen, Nora ;

Uthe, Regina ;

Giordano, Sara ;

Rosen, Steven ;

Hoskins, Kent ;

Von Roenn, Jamie ;

Jain, Sarika ;

Parini, Vamsi ;

Gradishar, William .

BREAST CANCER RESEARCH AND TREATMENT, 2015, 151 (03) :629-638

[7] Comprehensive molecular portraits of human breast tumours [J].

Koboldt, Daniel C. ;

Fulton, Robert S. ;

McLellan, Michael D. ;

Schmidt, Heather ;

Kalicki-Veizer, Joelle ;

McMichael, Joshua F. ;

Fulton, Lucinda L. ;

Dooling, David J. ;

Ding, Li ;

Mardis, Elaine R. ;

Wilson, Richard K. ;

Ally, Adrian ;

Balasundaram, Miruna ;

Butterfield, Yaron S. N. ;

Carlsen, Rebecca ;

Carter, Candace ;

Chu, Andy ;

Chuah, Eric ;

Chun, Hye-Jung E. ;

Coope, Robin J. N. ;

Dhalla, Noreen ;

Guin, Ranabir ;

Hirst, Carrie ;

Hirst, Martin ;

Holt, Robert A. ;

Lee, Darlene ;

Li, Haiyan I. ;

Mayo, Michael ;

Moore, Richard A. ;

Mungall, Andrew J. ;

Pleasance, Erin ;

Robertson, A. Gordon ;

Schein, Jacqueline E. ;

Shafiei, Arash ;

Sipahimalani, Payal ;

Slobodan, Jared R. ;

Stoll, Dominik ;

Tam, Angela ;

Thiessen, Nina ;

Varhol, Richard J. ;

Wye, Natasja ;

Zeng, Thomas ;

Zhao, Yongjun ;

Birol, Inanc ;

Jones, Steven J. M. ;

Marra, Marco A. ;

Cherniack, Andrew D. ;

Saksena, Gordon ;

Onofrio, Robert C. ;

Pho, Nam H. .

NATURE, 2012, 490 (7418) :61-70

[8] Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389 [J].

Kuznetsov, G ;

Towle, MJ ;

Cheng, HS ;

Kawamura, T ;

TenDyke, K ;

Liu, D ;

Kishi, Y ;

Yu, MJ ;

Littlefield, BA .

CANCER RESEARCH, 2004, 64 (16) :5760-5766

[9] YB-1: oncoprotein, prognostic marker and therapeutic target? [J].

Lasham, Annette ;

Print, Cristin G. ;

Woolley, Adele G. ;

Dunn, Sandra E. ;

Braithwaite, Antony W. .

BIOCHEMICAL JOURNAL, 2013, 449 :11-23

[10] DRUG DISCOVERY Complex synthesis yields breast-cancer therapy [J].

Ledford, Heidi .

NATURE, 2010, 468 (7324) :608-609

← 1 2 3 →